LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease

Journal of the Neurological Sciences

Volumn 214, Issue 1-2, 2003, Pages 11-16

  Slowik, Agnieszka ^a   Iskra, Tomasz ^a   Turaj, Wojciech ^a   Hartwich, Jadwiga ^a   Dembinska Kiec, Aldona ^a   Szczudlik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Large vessel disease; LDL phenotype B; Small vessel disease

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; LARGE VESSEL DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; SMALL VESSEL DISEASE; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0041828644     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00166-7     Document Type: Article

References (48)

1. Kannel W.B. Status of coronary heart disease risk factors. J. Nutr. Educ. 10:1978;10-14.
2. Lindenstrom E., Boysen G., Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ. 309:1994;11-15.
3. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 346:1995;1647-1653.
4. Christopher R., Kailasanatha K.M., Nagaraja D., Tripathi M. Case-control study of serum lipoprotein (a) and apolipoproteins A-I and B in stroke in the young. Acta Neurol. Scand. 94:1996;127-130.
5. Zenker G., Koltringer P., Bone G., Niederkorn K., Pfeiffer K., Jurgens G. Lipoprotein (a) as strong indicator for cerebrovascular disease. Stroke. 17:1986;942-945.
6. Hachinski V., Graffagnino C., Beaudry M., Bernier G., Buck C., Donner A.et al. Lipids and stroke: a paradox resolved. Arch. Neurol. 53:1996;303-308.
7. Albucher J.F., Ferrieres J., Ruidavets J.B., Guiraud-Chaumeil B., Perret B.P., Chollet F. Serum lipids in young patients with ischaemic stroke: a case-control study. J. Neurol. Neurosurg. Psychiatry. 69:2000;29-33.
8. Salonen R., Seppänen K., Rauramaa R., Salonen J.T. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis. 8:1988;788-792.
9. Fine-Edelstein J.S., Wolf P.A., O'Leary D.H., Poehlman H., Belanger A.J., Kase C.S.et al. Precursors of extracranial carotid atherosclerosis in the Framingham study. Neurology. 44:1994;1046-1050.
10. Bogousslavsky J., Castillo V., Kumral E., Henriques I., Van Melle G. Stroke subtypes and hypertension: primary hemorrhage vs. infarction, large- vs. small-artery disease. Arch. Neurol. 53:1996;265-269.
11. Cerrato P., Imperiale D., Fornengo P., Bruno G., Cassader M., Maffeis P.et al. Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease. Neurology. 58:2002;653-655.
12. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
13. Slyper A.H. Low-density lipoprotein density and atherosclerosis: unravelling the connection. JAMA. 272:1994;305-308.
14. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype A proposed genetic marker for coronary heart disease risk. Circulation. 82:1990;495-594.
15. Selby J.V., Austin M.A., Newman B., Zhang D., Quesenberry Ch.P. , Mayer E.J.et al. Lipids and insulin: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 88:1993;381-387.
16. Austin M.A., Kraus R.M. Genetic control of low-density-lipoprotein subclasses. Lancet. 2:1986;592-595.
17. Okamura H., Kawada M., Suehiro T., Ohno F. Low density lipoprotein subclass pattern B (small, dense LDL) in patients with cerebral infarction. J. Jpn. Atheroscler. Soc. 19:1991;1079.
18. Giroud M., Boutron M.C., Gras P., Gambert P., Lallemant C., Milan C.et al. Plasma lipoproteins in cortical infarction versus lacunar infarction with or without cardiac arrythmia, and in transient ischaemic attacks: a case control study. Neurol. Res. 14:1992;315-320.
19. Sato A., Asakura Y., Yokota C., Suzuki M., Tsushima M., Kuriyama Y.et al. Lipoprotein disorder in brain infarction and hemorrhage. Int. J. Clin. Lab. Res. 28:1998;39-46.
20. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L.et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke. 24:1993;35-41.
21. Report of the WHO Task Force on Stroke and Other Cerebrovascular Diseases. Stroke - 1989. Recommendations on stroke prevention, diagnosis and therapy. Stroke 1989;20:1407-31.
22. Swinkels D.W., Hendriks J.C., Demacker P.N., Stalenhoef A.F. Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells. Biochim. Biophys. Acta. 1047:1990;212-222.
23. Dormans T.P.J., Swinkels D.W., de Graf J., Hendriks J.C.M., Stalenhoef A.F.H., Demacker P.N.M. Single-spin density-gradient ultracentrifugation vs. gradient gel electrophoresis two methods for detecting low-density-lipoprotein heterogeneity compared. Clin. Chem. 37:1991;853-858.
24. Haglund H. Isoelectric focusing in pH gradients. A technique for fractionating and characterisation of amphotypes. Methods Biochem. Anal. 19:1971;1-4.
25. Menzel H.J., Utermann G. Apolipoprotein E phenotyping from serum by Western blotting. Electrophoresis. 7:1986;492-494.
26. de Graff J., Hak-Lemmers H.L.M., Hectors M.P.C., Demaker P.M.C., Hendrix J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Atheroscler. Thromb. 11:1991;298-306.
27. Miller B.D., Alserman E.L., Hasskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project. Circulation. 94:1996;2146-2153.
28. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonene R.et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
29. Steinberg D. Lipoproteins and pathogenesis of atherosclerosis. Circulation. 76:1987;508-514.
30. McCarron M.O., Delong D., Alberts M.J. APOE genotype as risk factor for ischemic cerebrovascular disease. A meta-analysis. Neurology. 53:1999;1308-1311.
31. Kuusisto J., Mykkanen L., Kervinen K., Kesaniemi Y.A., Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler. Thromb. Vasc. Biol. 15(9):1995;1280-1286.
32. Basun H., Corder E.H., Guo Z., Lannfelt L., Corder L.S., Manton K.G.et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke. 27:1996;1310-1315.
33. Couderc R., Mahieux F., Bailleul S., Fenelon G., Mary R., Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 24:1993;661-664.
34. Margaglione M., Seripa D., Gravina C., Grandone E., Vecchione G., Cappucci G.et al. Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischaemic stroke: an Italian case-control study. Stroke. 28:1998;399-403.
35. Kessler C., Spitzer C., Stauske D., Mende S., Stadlmuller J., Walther R.et al. The apolipoprotein e and beta-fibrinogen g/a-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;2880-2884.
36. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 77:1996;1179-1184.
37. Van Kooten F., van Krimpen J., Dippel D.W., Hoogerbrugge N., Koudstaal P.J. Lipoprotein (a) in patients with acute cerebral ischemia. Stroke. 27:1996;1231-1235.
38. Glader C.A., Stengmayr B., Boman J., Stenlund H., Weinehall L., Hallmans G.et al. Chlamydia pneumoniae antibodies and high lipoprotein (a) levels do not predict ischemic cerebral infarction. Stroke. 30:1999;2013-2018.
39. Ridker P.M., Stampfer M.J., Hennekens C.H. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 276(16):1995;1269-1273.
40. Peynet J., Beaudeux J.L., Woimant F., Flourie F., Giraudeaux V., Vicaut E.et al. Apolipoprotein (a) size polymorphism in young adults with ischemic stroke. Atherosclerosis. 142:1999;233-239.
41. Madden K.P., Karanjia P.N., Adams H.P. Jr., Clarke W.R. Accuracy of initial stroke subtype diagnosis in the TOAST study. Trial of ORG 10172 in Acute Stroke Treatment. Neurology. 45:1995;1975-1979.
42. Austin M.A., Mykkanen L., Kuusisto J., Edwards K.L., Nelson C.B.A., Haffner S.M.et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation. 92:1995;1770-1778.
43. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92:1993;141-146.
44. Lamon-Fava S. Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. Metabolism. 38:1989;921-925.
45. Williams P.T., Krauss R.M., Vranizan K.M., Wood P.D. Changes in lipoprotein subfraction during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation. 81:1990;1293-1304.
46. Gaw A., Packard C.J., Caslake M.J., Griffin B.A., Lindsay G.M., Thomson J.et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 108:1994;137-148.
47. Superko H.R., Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 95:1992;69-76.
48. Schamberger B.M., Geiss H.C., Ritter M.M., Schwandt P., Parhofer K.G. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J. Lipid Res. 41:2000;727-733.